Van Creveldkliniek Expert Centre for Rare Red Blood Cell Disorders
investigator initiated trials, hemolysis, iron overload, drug re-purposing, anemia, red blood cells,
Research aim
We are dedicated to revolutionizing lives of red blood cell disorder patients through innovative personalized medicine algorithms & rigorous trials for transformative treatments
About us
The Van Creveldkliniek Expert Centre for Rare Red Blood Cell Disorders has received accreditation from the Dutch Ministry of Health as an expertise center specializing in the treatment and research of benign hematology. Our primary research focus is on documenting organ damage resulting from chronic hemolysis, anemia, and iron overload, as well as identifying the associated pathophysiological pathways. Additionally, we are dedicated to the development of innovative treatment options for patients with rare anemias. This commitment encompasses a spectrum of studies, ranging from pharmaceutical-sponsored initiatives to early-phase investigator-led research, as well as participation in large-scale EU-funded trials that leverage cutting-edge technologies such as artificial intelligence and synthetic data. Furthermore, we actively explore drug repurposing strategies to broaden therapeutic options.
At the Van Creveldkliniek, we are deeply engaged in numerous trials and international registries, including the RADeep initiative within Eurobloodnet. Notably, one of our Principal Investigators, EJ van Beers, currently serves as the Chair of the Sickle Cell Outcome Research Consortium. Additionally, Dr. van Beers acts as the coordinator of the TFA for research and trials for Benign Hematology within the European Reference Network for Rare Hematological Diseases (Eurobloodnet), which comprises 103 expert centres across Europe.